August 23, 2023
With funding from The Leona M. and Harry B. Helmsley Charitable Trust, Jeremy Pettus, MD, an associate professor of medicine and board-certified endocrinologist who specializes in treating diabetes at UC San Diego Health, is leading a study on Liver Targeted Insulin (LTI) in Type 1 diabetes.
April 21, 2023
UC San Diego researchers describe a key player in the defense mechanism that safeguards against excessive insulin in the body, which can be as harmful as too little.
April 11, 2024
Researchers from UC San Diego have discovered the biochemical workings of an old-fashioned diabetes drug, and it’s helping them develop new, safer alternatives.
September 9, 2021
UC San Diego School of Medicine researchers will receive $6.4 million in National Institutes of Health grant funding to study how external signals and genetic variations influence the behavior of one cell type in particular: insulin-producing beta cells in the pancreas.
November 3, 2016
By removing the protein galectin-3 (Gal3), a team of investigators led by University of California School of Medicine researchers were able to reverse diabetic insulin resistance and glucose intolerance in mouse models of obesity and diabetes.
August 6, 2012
…foreign invaders, also plays an unexpected role in mediating insulin resistance – the central characteristic of type 2 diabetes, which afflicts an estimated 26 million Americans.
March 25, 2014
…them under the skin of diabetic mouse models, sufficient insulin is produced to maintain glucose levels without unwanted potential trade-offs of the technology.
February 23, 2015
…inflammatory molecule LTB4 promotes insulin resistance, a first step in developing type 2 diabetes. What’s more, the team found that genetically removing the cell receptor that responds to LTB4, or blocking it with a drug, improves insulin sensitivity in obese mice. The study is published Feb. 23 by Nature Medicine.
April 11, 2013
…beta cells, whose role is to produce and release insulin. The discovery suggests a new therapeutic target for treating dysfunctional beta cells and type 2 diabetes, a disease affecting more than 25 million Americans.
February 7, 2018
Treating obese mice with catestatin (CST), a peptide naturally occurring in the body, showed significant improvement in glucose and insulin tolerance and reduced body weight, report University of California San Diego School of Medicine researchers.
